Skip to Main Content

Paper Details

Safety of gemtuzumab ozogamicin as monotherapy or combination therapy in an expanded-access protocol for patients with relapsed or refractory acute myeloid leukemia.
Leuk Lymphoma
8
2020
AML, APL, Gemtuzumab ozogamicin, Hepatotoxicity, Patients, acute myeloid leukemia, acute promyelocytic leukemia, drug, gemtuzumab ozogamicin, myelodysplastic syndrome, patients, veno-occlusive disease
Author NameAffiliation
Richard AplencThe Children's Hospital of Philadelphia
Richard AplencThe Children's Hospital of Philadelphia
Tara L LinUniversity of Kansas Medical Center
  • 1 - 3

Datasets

Release 1.2